mAbsolve was founded in the UK by pioneers of therapeutic antibody development and engineering from both Oxford and Cambridge. We have experienced the clinical challenges caused by incomplete silencing of antibodies using LALA, aglycosylated or IgG4 variants. To address this we have developed a best-in-class solution for silencing of antibody effector function. Our STR technology is the only truly silent Fc and we are actively licensing it for therapeutic development of antibodies or Fc fusion proteins.
First and only truly silent antibody Fc domain
Only silencing technology widely available to license
Licensable antibody technology to eliminate Fc receptor binding
- custom services